Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2007-04-03
2007-04-03
Helms, Larry R. (Department: 1643)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S070100, C435S069100, C435S070300, C435S072000, C536S023400, C536S023500, C514S04400A
Reexamination Certificate
active
09493480
ABSTRACT:
The present invention is generally directed to HER-2
eu fusion proteins, nucleic acid molecules encoding HER-2
eu fusion proteins, viral vectors expressing HER-2
eu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2
eu fusion proteins and/or nucleic acid molecules encoding the HER-2
eu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2
eu protein, including for uses in the treatment of malignancies associated with the HER-2
eu oncogene.
REFERENCES:
patent: 4803072 (1989-02-01), Dalton et al.
patent: 5723130 (1998-03-01), Hancock et al.
patent: 5726023 (1998-03-01), Cheever et al.
patent: 5801005 (1998-09-01), Cheever et al.
patent: 5811098 (1998-09-01), Plowman et al.
patent: 5846538 (1998-12-01), Cheever et al.
patent: 5869445 (1999-02-01), Cheever et al.
patent: 5876712 (1999-03-01), Cheever et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 5976546 (1999-11-01), Laus et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6080409 (2000-06-01), Laus et al.
patent: 6146632 (2000-11-01), Momin et al.
patent: 6270769 (2001-08-01), Raychaudhuri et al.
patent: 6287569 (2001-09-01), Kipps et al.
patent: 6333169 (2001-12-01), Hudziak et al.
patent: 6429199 (2002-08-01), Krieg et al.
patent: 6664370 (2003-12-01), Cheever et al.
patent: 6734172 (2004-05-01), Scholler et al.
patent: 6942862 (2005-09-01), Cheever et al.
patent: 6953573 (2005-10-01), Cheever et al.
patent: 7005498 (2006-02-01), Steinaa et al.
patent: 2002/0018766 (2002-02-01), Roberts et al.
patent: 2002/0155527 (2002-10-01), Stuart et al.
patent: 0474727 (1997-07-01), None
patent: 0444181 (2001-10-01), None
patent: WO 90/14357 (1990-11-01), None
patent: WO91/02062 (1991-02-01), None
patent: WO 91/02062 (1991-02-01), None
patent: WO91/18926 (1991-12-01), None
patent: WO95/17210 (1995-06-01), None
patent: WO96/02555 (1996-02-01), None
patent: WO96/18409 (1996-06-01), None
patent: WO 96/18409 (1996-06-01), None
patent: WO 96/30514 (1996-10-01), None
patent: WO98/25574 (1998-06-01), None
patent: WO99/46988 (1999-09-01), None
patent: WO 99/46988 (1999-09-01), None
patent: WO99/57981 (1999-11-01), None
patent: WO00/04927 (2000-02-01), None
patent: WO00/20027 (2000-04-01), None
patent: WO00/29582 (2000-05-01), None
patent: WO00/44899 (2000-08-01), None
patent: WO 00/44899 (2000-08-01), None
patent: WO01/74855 (2001-10-01), None
patent: WO 01/74855 (2001-10-01), None
Dermer, Bio/Technology, vol. 12, p. 320, Mar. 1994.
Osband and Ross, Immunotherapy, pp. 193-195, 1990.
Cornelia I. Bargmann et al., “TheNeuOncogene Encodes an Epidermal Growth Factor Receptor-Related Protein,” Jan. 1986, Nature, vol. 319, pp. 226-230.
Yasuhiro Nagata et al., “Peptides Derived From a Wild-Type Murine Proto-Oncogene c-erbB-2/HER2
euCan Induce CTL and Tumor Suppression in Syngeneic Hosts,” 1997, The American Association of Immunologists, The Journal of Immunology 159: 1336-1343.
Disis et al., “Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein”,Journal of Immunology, XP-002139506: 3150-3158 (1996).
Ezzel et al., Cancer “Vaccines”: An Idea Whose Time Has Come?, J. NIH research 7:46-49 (1995).
Spitler, Cancer Vaccines: The Interferon Analogy, Cancer Biotherapy 10(1):1-3 (1995).
Disis et al., Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self-Protein, The J. of Immunology 156:3151-3158 (1996).
Disis et al., Immunization with Homologous Foreign Proteins Generates Immunity Against “Self” Tumor Antigens, The FASEB Journal 10(6):A1470 (1996) ABSTRACT from Meetings, New Orleans, LA Jun. 2-6, 1996.
Disis and Cheever, Advances in Cancer Research 71:343-371 (1997).
Bernhard et al., Vaccination against the HER-2
u oncogenic protein, Endocrine-Related Cancer 9:33-44 (2002).
Chamberlain and Kaufman, Inoovations and strategies for the development of anticancer vaccines, Expert Opinion on Pharmacotherapy 1(4):603-614 (2000).
Cheever Martin A.
Gheysen Dirk
Campen Virginia G.
Corika Corporation
Helms Larry R.
Holleran Anne L.
SmithKline Beecham Biologicals (S.A.)
LandOfFree
HER-2/neu fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HER-2/neu fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HER-2/neu fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3804318